Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-09-14

Clinical Trial Update: Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating FX006 for hip osteoarthritis was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FX006

Snippet

Sponsor: Pacira Pharmaceuticals, Inc | Conditions: Osteoarthritis, Hip | Phase 3 | Status: TERMINATED | Results posted: 2020-09-14